# A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

Study · id `cardio:ct-nct07753993` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07753993](<https://clinicaltrials.gov/study/NCT07753993>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07753993

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7000 participants.

## Technical summary

Registry record NCT07753993. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-21 (actual); primary completion 2030-10-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 7000 participants (planned count; ClinicalTrials.gov record NCT07753993, source copy `cardio:ctgov-nct07753993-2026-09-09`, retrieved 2026-10-26)
- Started: 2026-08-21 (actual) (ClinicalTrials.gov record NCT07753993, source copy `cardio:ctgov-nct07753993-2026-09-09`, retrieved 2026-10-26)
- Primary completion: 2030-10-04 (anticipated) (ClinicalTrials.gov record NCT07753993, source copy `cardio:ctgov-nct07753993-2026-09-09`, retrieved 2026-10-26)
- Completion: 2030-10-04 (anticipated) (ClinicalTrials.gov record NCT07753993, source copy `cardio:ctgov-nct07753993-2026-09-09`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; Chile; China; Czechia; Denmark; Finland; France; Germany; Greece; Hungary; India; Indonesia; Israel; Italy; Japan; Malaysia; Mexico; Norway; Peru; Philippines; Poland; Romania; Serbia; South Korea; Spain; Sweden; Taiwan; Thailand; Ukraine; United Arab Emirates; United Kingdom; Vietnam (ClinicalTrials.gov record NCT07753993, source copy `cardio:ctgov-nct07753993-2026-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07753993-2026-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
- Acronym: Elevate-CKD
- Condition: Chronic Kidney Disease
- Intervention (Drug): Elecoglipron
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: bd2cc2d7a6465119e1dfad0f8e67815a6f9d32f501feed8867a618882c79530a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
